The Deerborne Group to Attend American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, May 28, 2025 /PRNewswire/ -- The Deerborne Group, a leading boutique consultancy specializing in genomics and precision diagnostics, today announced it will attend the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30–June 3 in Chicago, IL.
Founded in 2020, The Deerborne Group serves corporate leaders, venture capital, and private equity firms across the life sciences sector. The firm delivers evidence-based strategic guidance that helps clients unlock market potential, accelerate commercialization, and navigate the evolving landscape of precision medicine. Its consultants bring decades of real-world operating experience, translating scientific advancement into business results.
ASCO remains one of the world's most influential oncology gatherings, convening global stakeholders to discuss cutting-edge research, transformative technologies, and next-generation care models. Deerborne's presence reflects its commitment to remaining at the forefront of cancer innovation and shaping the future of diagnostic strategy.
"Our clients rely on us to translate complexity into clarity," said Jeffrey Jones, founder and Chairman at The Deerborne Group. "ASCO provides a forward-looking view of where oncology is headed—and we use that insight to help our clients stay ahead, de-risk investments, and capture first-mover advantage."
The Deerborne Group's Chairman, Jeffrey Jones, and other team members will be available throughout the conference and are excited to share how the firm can help their clients accelerate insights into value with their innovative and differentiated suite of consulting services. To learn more, please contact us to schedule a meeting.
About The Deerborne Group
The Deerborne Group is a leading boutique management consultancy focused on genomics and precision diagnostics. Founded in 2020, the firm advises Fortune 500 companies, venture capital firms, and private equity groups on high-impact corporate, commercial, and operational strategies. With a data-driven approach and deep sector expertise, The Deerborne Group helps clients uncover growth opportunities, mitigate risk, and solve complex business challenges in a dynamic healthcare landscape.
The firm's capabilities span strategy development, go-to-market planning, market access and reimbursement, clinical trial and regulatory strategy, CLIA lab operations, KOL and advisory board engagement, and commercial due diligence. Deerborne also provides interim executive leadership and supports clients across the full lifecycle—from innovation to execution.
Follow The Deerborne Group on LinkedIn, Facebook, Twitter or Instagram.
Media Contact: Liz Dowling
+1 (760) 822 3412
SOURCE The Deerborne Group
Share this article